MedTrace Logo

Pentoxifylline Therapy in Biliary Atresia

NCT01774487 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-01-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.

Conditions

  • Biliary Atresia

Interventions

DRUG

Pentoxifylline

20 mg/kg/day divided in 3 doses, given orally for 90 days

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Sanjiv Harpavat, MD PhD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
180 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-04
Primary Completion
2018-02-07
Completion
2023-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01774487 on ClinicalTrials.gov